Oncology News and Research

RSS

Oncology, meaning bulk, mass, or tumor, and the suffix ''-logy'', meaning "study of") is a branch of medicine that deals with tumors (cancer). A medical professional who practices oncology is an ''oncologist''.

HOPA Oncology Pharmacy Practice Management Program to be held on Sept. 18-19, 2015 in Illinois

The Hematology/Oncology Pharmacy Association (HOPA) will present the HOPA Oncology Pharmacy Practice Management Program at the Hilton Rosemont/Chicago O'Hare on September 18-19, 2015, in Rosemont, IL.

9 Jun 2015

Earlier introduction of palliative care in advanced cancer patients associated with lower hospital costs

Earlier introduction of palliative care for patients hospitalized with advanced cancer is associated with lower hospital costs, according to a new study published in the Journal of Clinical Oncology.

9 Jun 2015

Ibrutinib shows promise in CLL/SLL

The addition of ibrutinib to bendamustine and rituximab significantly prolongs progression-free survival in patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma, according to the HELIOS trial.

8 Jun 2015

Jazz enrolls first patients in JZP-110 Phase 3 study for treatment of EDS in patients with narcolepsy or OSA

Jazz Pharmaceuticals plc announced today that the first patients have been enrolled in a Phase 3 clinical development program evaluating the safety and efficacy of its investigational drug candidate, JZP-110, as a wake-promoting agent in the treatment of excessive daytime sleepiness (EDS) in adult patients with narcolepsy or with obstructive sleep apnea (OSA).

8 Jun 2015

Merck KGaA, Darmstadt, Germany forms Global Fertility Alliance with Illumina and Genea

Merck KGaA, Darmstadt, Germany, a leading company for innovative and top-quality high-tech products in healthcare, life science and performance materials today announced the formation of the Global Fertility Alliance, a new collaboration to advance excellence in fertility technologies and processes within the assisted reproductive treatment (ART) laboratory.

From Illumina, Inc. 8 Jun 2015

People now have powerful new option for relieving dry mouth symptoms

People who suffer from dry mouth, or xerostomia, now have a powerful new option for relieving their symptoms. Building on the success of its antioxidant oral care product line, Dallas-based PerioSciences LLC is launching Dry Mouth AO ProGel and a new MILD formula of its Hydrating AO ProRinse. The new products, along with the established Hydrating AO ProRinse and AO ProToothpaste, provide a complete Hydrating Oral Care System.

8 Jun 2015

Innovative QI program speeds recovery in patients undergoing colon and rectal operations

Patients undergoing colon and rectal operations who participated in an innovative quality improvement (QI) program to speed their recovery and enhance results experienced shorter hospitalizations, reduced infection rates, and lower hospital costs, according to new study results.

8 Jun 2015

Merck Canada announces conditional approval of KEYTRUDA (pembrolizumab) for melanoma treatment

Merck Canada Inc. announced today that KEYTRUDATM (pembrolizumab) was authorized for sale with conditions by Health Canada on May 19, 2015. KEYTRUDA is a humanized monoclonal antibody that works by increasing the ability of the body's immune system to fight advanced melanoma, the most serious form of skin cancer. It is the first of a new class of therapies called anti-PD-1s approved in Canada.

8 Jun 2015

Non-invasive prenatal testing can detect maternal cancer at early stage

Non-invasive prenatal testing (NIPT) for chromosomal foetal disorders is used increasingly to test for conditions such as Down's syndrome. NIPT examines DNA from the foetus in the mother's blood, and therefore does not carry the risk of miscarriage involved in invasive testing methods.

7 Jun 2015

Janssen begins rolling submission of daratumumab BLA to FDA for treatment of patients with multiple myeloma

Janssen Research & Development, LLC has initiated the rolling submission of its Biologic License Application (BLA) for daratumumab to the U.S. Food and Drug Administration (FDA) for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy, including a proteasome inhibitor (PI) and an immunomodulatory agent (IMiD), or who are double refractory to a PI and an IMiD.

7 Jun 2015

PALOMA3 supports palbociclib use in advanced breast cancer

Advanced breast cancer patients who have failed prior endocrine treatment may receive a progression-free survival benefit if palbociclib is added to fulvestrant, a phase III trial indicates.

5 Jun 2015

IDMC recommends continuation of Argos’ ADAPT phase 3 trial of AGS-003 in mRCC patients

Argos Therapeutics Inc., an immuno-oncology company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer based on the Arcelis technology platform, today announced an independent data monitoring committee (IDMC) has recommended the continuation of the company’s pivotal phase 3 ADAPT clinical trial of AGS-003 for the treatment of metastatic renal cell carcinoma (mRCC) following the first of three planned interim data analyses.

5 Jun 2015

Seattle Children's opens enrollment for first clinical trial of Tumor Paint BLZ-100 for children with brain tumors

Seattle Children's today announced the opening of patient enrollment for the first clinical research trial of the drug Tumor Paint BLZ-100, which is designed to improve surgical outcomes in children with brain tumors – the most common solid tumor cancer in kids.

5 Jun 2015

Ibrutinib (IMBRUVICA) improves survival in treatment-naïve patients with chronic lymphocytic leukemia

Today, Pharmacyclics LLC, an AbbVie company, announced that ibrutinib (IMBRUVICA) improved progression-free survival (PFS; primary endpoint) and multiple secondary endpoints including overall survival (OS) and overall response rate (ORR) in treatment-naïve patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL, respectively) in the final analysis of the Phase III RESONATE™-2 (PCYC-1115) trial.

5 Jun 2015

Our Lady of the Lake Children's Hospital opens pediatric specialty clinic in Lafayette, Louisiana

Our Lady of the Lake Children's Hospital opened its first pediatric specialty clinic outside of the Baton Rouge area on June 3. The Pediatric Specialty Clinic in Lafayette, Louisiana will offer specialized outpatient care for pediatric gastroenterology.

5 Jun 2015

$Elotuzumab boosts response in relapsed, refractory multiple myeloma$

Elotuzumab boosts response in relapsed, refractory multiple myeloma

Addition of the immunostimulatory antibody elotuzumab to the combination of lenalidomide and dexamethasone improves progression-free survival and the overall response rate in patients with relapsed or refractory multiple myeloma, research suggests.

4 Jun 2015

Gastrostomy methods equivalent in amyotrophic lateral sclerosis

The ProGas study results show that three methods of gastrostomy are equally good in terms of complications and survival in patients with amyotrophic lateral sclerosis.

4 Jun 2015

Regulus Therapeutics begins RG-012 Phase I clinical study for treatment of Alport syndrome

Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today that dosing has begun in a first-in-human Phase I clinical study of RG-012, a single stranded, chemically modified oligonucleotide that binds to and inhibits the function of microRNA-21 ("miR-21").

4 Jun 2015

CASI files application with CFDA to conduct ENMD-2076 Phase 2 trial in fibrolamellar carcinoma patients

CASI Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the acquisition, development and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the global market with a commercial focus on China, announced today that it has filed an application with China's Food and Drug Administration to conduct a Phase 2 clinical trial in fibrolamellar carcinoma (FLC) patients in China for its proprietary drug candidate, ENMD-2076.

4 Jun 2015

EMA, ESMO and RCE joint workshop focuses on rare cancers and chordoma

To date, there is no drug approved for medical therapy of chordoma patients. Supporting research for chordoma (a very rare cancer arising from the skull base or the spine and affecting only one person in a million per year) was the focus of talks that took place on 30 April 2015 at the European Medicines Agency in London. The workshop was attended by patients, oncologists, pathologists, regulators, statisticians and industry representatives.

4 Jun 2015

Oncology News and Research

Further Reading

HOPA Oncology Pharmacy Practice Management Program to be held on Sept. 18-19, 2015 in Illinois

Earlier introduction of palliative care in advanced cancer patients associated with lower hospital costs

Ibrutinib shows promise in CLL/SLL

Jazz enrolls first patients in JZP-110 Phase 3 study for treatment of EDS in patients with narcolepsy or OSA

Merck KGaA, Darmstadt, Germany forms Global Fertility Alliance with Illumina and Genea

People now have powerful new option for relieving dry mouth symptoms

Innovative QI program speeds recovery in patients undergoing colon and rectal operations

Merck Canada announces conditional approval of KEYTRUDA (pembrolizumab) for melanoma treatment

Non-invasive prenatal testing can detect maternal cancer at early stage

Janssen begins rolling submission of daratumumab BLA to FDA for treatment of patients with multiple myeloma

PALOMA3 supports palbociclib use in advanced breast cancer

IDMC recommends continuation of Argos’ ADAPT phase 3 trial of AGS-003 in mRCC patients

Seattle Children's opens enrollment for first clinical trial of Tumor Paint BLZ-100 for children with brain tumors

Ibrutinib (IMBRUVICA) improves survival in treatment-naïve patients with chronic lymphocytic leukemia

Our Lady of the Lake Children's Hospital opens pediatric specialty clinic in Lafayette, Louisiana

Elotuzumab boosts response in relapsed, refractory multiple myeloma

Gastrostomy methods equivalent in amyotrophic lateral sclerosis

Regulus Therapeutics begins RG-012 Phase I clinical study for treatment of Alport syndrome

CASI files application with CFDA to conduct ENMD-2076 Phase 2 trial in fibrolamellar carcinoma patients

EMA, ESMO and RCE joint workshop focuses on rare cancers and chordoma

Event guide: 10th CAR-TCR Summit eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News